Pitch: a US startup using AI to discover bioactive compounds in plants for human health applications.

Source: Brightseed

ID card

• HQ: US
• Founded: 2017
• Funding: $120.8M
• Last Funding: $68M (05/2022)
• Corporate investors: ADM
• Partnerships: Danone, ADM, Ocean Spray
• Innovations: AI platform mapping bioactive compounds and predicting their impact on human health
• Competitors: Shiru (US), Nuritas (Ireland), NotCo (Chile)

More insights

• Brightseed uses its proprietary AI platform to analyse millions of plant compounds and identify bioactives with specific health benefits (gut health, metabolic health, immunity).
• It aims to accelerate ingredient discovery timelines compared to traditional R&D.
• Its business model combines:
  • Its AI platform access (subscription/collaboration): helping companies identify, prioritise and validate bioactive ingredients before commercialisation.
  • Ingredient commercialisation (own bioactives): it recently positioned its first commercial ingredient as a “GLP-1 companion”, supported by clinical validation, and available in multiple formats (capsules, tablets, powder).
• Brightseed indicates it will not expand its own ingredient pipeline beyond initial launches, reinforcing a platform-first model with partner-led commercialisation.
• It has established 40+ partnerships across food, health and personal care, signalling industry validation and early adoption of its AI-driven discovery model.

For Symrise

Why did we select the startup?

Brightseed enables biology-driven discovery, identifying clinically relevant bioactives that support health claims in food, beverage and nutraceutical applications.

Why now?

The startup is entering a commercialisation phase, combining a mature AI discovery platform, a growing number of corporate partnerships and initial ingredient launches.

biometacontrol-2.avif

Source: Brightseed